Table 3.
Estimates for the association between the CYP2B6 metabolizer phenotype (using rs3745274 and rs28399499) with virologic response1 to NNRTI-based HAART regimens in women who were naïve to antiretroviral drugs (N=91).
| Metabolizer Phenotype2 | Responders (%) | Non-responders (%) | Crude | Adjusted for SR Race/Ethnicity3 | Adjusted for top three PCs4 |
|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | |||
| Extensive | 28 (40) | 12 (57) | 1.00 | 1.00 | 1.00 |
| Intermediate | 33 (47) | 9 (43) | 1.56 (0.52-4.88) | 1.66 (0.47-6.11) | 2.90 (0.79-12.28) |
| Slow | 9 (13) | 0 | 5.00 (0.70-inf) | 7.69 (1.04-inf) | 13.44 (1.66-inf) |
| p trend exact | 0.09 | 0.04 | 0.005 |
1
Virologic response defined as achievement of undetectable viral load up to 54 weeks after self- reported initiation of NNRTI-based regimen
2
Extensive = no minor alleles at either rs3745274 or rs28399499 Intermediate = one minor allele at either rs3745274 or rs28399499 Slow = two minor alleles at either rs3745274 or rs28399499, or one minor allele at both polymorphisms
3
Adjusted for self-reported race/ethnicity (White, Hispanic, African American, Asian/Other)
4
Adjusted for the top three genetic ancestry principal components (PCs)